Pharsight

Drugs that contain Raltegravir Potassium

1. Isentress patents expiration

ISENTRESS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169780 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(6 months ago)

US8852632 MSD SUB MERCK Pharmaceutical formulation containing a release rate controlling composition
Jan, 2028

(3 years from now)

US7754731 MSD SUB MERCK Potassium salt of an HIV integrase inhibitor
Mar, 2029

(4 years from now)

US8771733 MSD SUB MERCK Pharmaceutical composition containing an anti-nucleating agent
Jun, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7435734 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7217713

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(a year ago)

US7435734

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(a year ago)

US7169780

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(17 days ago)

US7754731

(Pediatric)

MSD SUB MERCK Potassium salt of an HIV integrase inhibitor
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Nov 22, 2020
Pediatric Exclusivity(PED) May 22, 2021
New Dosage Form(NDF) Dec 21, 2014
M(M-114) Mar 28, 2015

Market Authorisation Date: 21 December, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET, CHEWABLE;ORAL; TABLET;ORAL; POWDER;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

2. Isentress Hd patents expiration

ISENTRESS HD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169780 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(6 months ago)

US7754731 MSD SUB MERCK Potassium salt of an HIV integrase inhibitor
Mar, 2029

(4 years from now)

US8771733 MSD SUB MERCK Pharmaceutical composition containing an anti-nucleating agent
Jun, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7435734 MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7217713

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(a year ago)

US7435734

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(a year ago)

US7169780

(Pediatric)

MSD SUB MERCK N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(17 days ago)

US7754731

(Pediatric)

MSD SUB MERCK Potassium salt of an HIV integrase inhibitor
Sep, 2029

(5 years from now)

US9649311 MSD SUB MERCK Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(6 years from now)

US9649311

(Pediatric)

MSD SUB MERCK Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(7 years from now)

US10772888 MSD SUB MERCK Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 26, 2020
New Dosing Schedule(D-167) May 26, 2020
New Patient Population(NPP) Dec 21, 2014
Pediatric Exclusivity(PED) May 22, 2021
M(M-114) Mar 28, 2015
New Chemical Entity Exclusivity(NCE) Oct 12, 2012

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage

ISENTRESS HD family patents

Family Patents